Inversago Pharma
in Peripheral CB1
Blockade
Full Potential of
Peripherally-acting
CB1 Inverse Agonists
About Inversago Pharma
Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as diabetic nephropathy, Non-Alcoholic Steatohepatitis (NASH), complications of obesity, hypertriglyceridemia (HTG) and Type 1 Diabetes (T1D), Prader-Willi Syndrome (PWS), as well as fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF).
The Peripheral CB1 Company
Targeting metabolic diseases in need of better adapted treatment options
Inversago has the know-how, technology and clinical expertise to develop safe and potent first-in-class inverse agonists of peripheral CB1 receptors to address a broad range of medical indications (conditions related to obesity such as diabetes (diabetic nephropathy (DN), hypertriglyceridemia (HTG) and type 1 diabetes)), liver diseases (NASH), Prader-Willi Syndrome (PWS) or fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD).
INV-202, our lead program targeting metabolic disorders, is a next generation, peripherally-acting CB1 inverse agonist in clinical development. Our other candidate molecules targeting the peripheral CB1 pathway have also shown activity in several preclinical models.
Our Approach
A safe and potent CB1 inhibitor would have the potential to block or reverse (inverse agonize) the biological processes induced by supraphysiological CB1 activation and provide a novel treatment to patients.